List of Excipients in Branded Drug PREDNISOLONE SODIUM PHOSPHATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Seton Pharmaceuticals LLC	PREDNISOLONE SODIUM PHOSPHATE	prednisolone sodium phosphate	13925-166	EDETATE DISODIUM
Seton Pharmaceuticals LLC	PREDNISOLONE SODIUM PHOSPHATE	prednisolone sodium phosphate	13925-166	METHYLPARABEN
Seton Pharmaceuticals LLC	PREDNISOLONE SODIUM PHOSPHATE	prednisolone sodium phosphate	13925-166	RASPBERRY
Seton Pharmaceuticals LLC	PREDNISOLONE SODIUM PHOSPHATE	prednisolone sodium phosphate	13925-166	SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

Generic Drugs Containing PREDNISOLONE SODIUM PHOSPHATE

Company	Ingredient	NDC	Excipient
PAI Holdings LLC dba PAI Pharma	prednisolone sodium phosphate	0121-0759	EDETATE DISODIUM
PAI Holdings LLC dba PAI Pharma	prednisolone sodium phosphate	0121-0759	GLYCERIN
PAI Holdings LLC dba PAI Pharma	prednisolone sodium phosphate	0121-0759	HIGH FRUCTOSE CORN SYRUP
PAI Holdings LLC dba PAI Pharma	prednisolone sodium phosphate	0121-0759	HYDROXYETHYL CELLULOSE

What are the Most Frequently-Used Excipients in PREDNISOLONE SODIUM PHOSPHATE?

# Of NDCs	Excipient
3	ALCOHOL
1	AQUA
3	BENZALKONIUM CHLORIDE
13	CORN SYRUP

Prednisolone Sodium Phosphate Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

Prednisolone sodium phosphate is an established, generic corticosteroid with limited composition-of-matter protection and low barriers to basic oral-solution development. Commercial differentiation depends on palatability, pediatric usability, preservative systems, stability, packaging, dosing accuracy, and regulatory execution rather than new-molecule exclusivity. The strongest opportunities are alcohol-free pediatric liquids, preservative-optimized multidose products, unit-dose presentations, orally disintegrating tablets, and specialty formulations with improved adherence or reduced administration burden.

What is prednisolone sodium phosphate and where is it used?

Prednisolone sodium phosphate is a water-soluble prodrug salt of prednisolone used in systemic corticosteroid products. It is particularly suitable for aqueous oral formulations because its phosphate salt improves water solubility relative to less-soluble prednisolone derivatives.

The principal dosage forms are:

Dosage form	Commercial rationale	Main formulation issue
Oral solution	Pediatric dosing, flexible dose adjustment	Taste, microbial control, chemical stability
Orally disintegrating tablet	No-water administration and portability	Disintegration, moisture sensitivity, dose uniformity
Ophthalmic solution	Local corticosteroid delivery	Sterility, ocular tolerability, preservative exposure
Unit-dose oral liquid	Caregiver convenience and reduced contamination risk	Packaging cost and dose-volume limitations
Compounded liquid	Hospital and pharmacy use	Stability, beyond-use dating, excipient variability

Prednisolone sodium phosphate oral products are commonly used when patients cannot swallow tablets or require weight-based dosing. FDA labeling for branded and generic products identifies pediatric and adult inflammatory, allergic, and autoimmune indications, subject to the specific product label.[1-3]

What excipients are most important in prednisolone sodium phosphate formulations?

The excipient strategy should be built around five performance targets: solubility, pH control, taste, microbiological quality, and shelf-life stability.

Buffer and pH-control system

Prednisolone sodium phosphate formulations generally require controlled pH because phosphate ester stability and drug solubility are pH-dependent. Common formulation approaches use phosphate buffers, citrate systems, or other pharmaceutically acceptable acids and bases.

The buffer must balance:

• Chemical stability of prednisolone sodium phosphate
• Acceptable oral taste
• Compatibility with preservatives
• Compatibility with the container closure
• Physiological tolerability
• Minimal impact on assay and degradation products

A high-buffer-capacity system may improve pH consistency but can produce a more noticeable taste and increase excipient load. A lower-capacity system can improve palatability but may be more vulnerable to pH drift during storage.

A development program should evaluate pH at release, after accelerated aging, after open-container storage, and after repeated dosing from multidose packaging.

Sweeteners and taste masking

Taste is the most commercially important excipient issue for pediatric oral liquids. Prednisolone products can have a bitter or medicinal taste, and sweetness alone may not adequately mask the active ingredient.

Common options include:

• Sucrose
• Sorbitol
• Sucralose
• Saccharin sodium
• Acesulfame potassium
• Aspartame, where appropriate
• Polyols such as glycerin or mannitol

Sucrose can provide a strong taste profile but increases sugar content, viscosity, and dental-care concerns. Sorbitol and other polyols can create gastrointestinal tolerability issues at higher exposure. Aspartame is unsuitable for patients with phenylketonuria and requires appropriate labeling. Sucralose and saccharin may improve sweetness with lower mass loading but can leave an aftertaste.

A commercially attractive product would use a taste-masking system that works at the lowest practical excipient concentration. Flavor selection should be based on pediatric sensory testing rather than adult preference. Fruit flavors, including cherry, grape, berry, and orange profiles, are common candidates, but the best flavor depends on concentration, buffer system, preservative, and packaging.

Viscosity modifiers

Viscosity affects dose accuracy, pourability, mouthfeel, sedimentation risk, and caregiver acceptance. Suitable agents may include:

• Glycerin
• Sorbitol
• Hydroxyethylcellulose
• Hypromellose
• Xanthan gum
• Sodium carboxymethylcellulose

A modest viscosity increase can reduce splashing and improve dosing with oral syringes. Excessive viscosity can increase residual volume in the bottle or syringe and produce inconsistent delivered doses. For pediatric products, the target should favor accurate syringe withdrawal over a thick, syrup-like texture.

Preservatives and antimicrobial control

Multidose oral solutions require an antimicrobial-control strategy unless the product is demonstrated to remain microbiologically suitable without a preservative. Possible preservatives include sodium benzoate, benzoic acid, potassium sorbate, and parabens, depending on pH, concentration, and regulatory acceptability.

Preservative performance is highly pH-dependent. The formulation should be tested through antimicrobial effectiveness testing under the applicable pharmacopeial standard, including USP <51> where relevant.[4]

Preservative-free products can create a premium opportunity, but they require a different commercial architecture:

• Single-use or unit-dose containers
• Shorter in-use storage periods
• Aseptic manufacturing controls
• Stronger packaging and contamination testing
• Potentially higher manufacturing cost

Preservative minimization may be valuable for infants, patients with excipient sensitivities, and ophthalmic products. It is not automatically a superior strategy because preservative-free packaging materially increases cost and supply-chain complexity.

Chelators and antioxidants

Chelating agents such as disodium edetate may improve stability by binding trace metals that catalyze degradation. Antioxidants may be considered if oxidative pathways are identified during stress testing.

These excipients should be used only where supported by degradation data. Unnecessary excipients increase regulatory review burden, labeling complexity, and potential intolerance without creating a defensible product advantage.

What formulation patents could protect prednisolone sodium phosphate products?

Core prednisolone sodium phosphate protection is commercially weak because the active ingredient and conventional dosage forms have been known for decades. The relevant intellectual-property opportunity is a formulation, delivery, packaging, or manufacturing patent.

Potential claim categories include:

Patent category	Potential claim subject	Commercial defensibility
Taste-masked liquid	Specific sweetener-flavor-buffer combination	Moderate if performance is unexpected
Stable oral solution	Defined pH, impurity profile, and storage conditions	Moderate
Preservative-free product	Unit-dose package and contamination-control method	Moderate
ODT formulation	Porous matrix, disintegrant system, and moisture barrier	Moderate to strong if differentiated
Pediatric dosing system	Bottle, adapter, syringe, and dose-control configuration	Moderate
Ophthalmic product	Sterile, low-irritation formulation and container	Moderate
Manufacturing process	Controlled conversion, drying, or impurity reduction	Moderate if process produces measurable quality benefits
Packaging	Light-resistant, low-sorption, or dose-preserving container	Narrow but commercially useful

A patent application should connect composition claims to measurable performance. Useful evidence includes:

• Lower bitterness scores
• Faster onset of taste masking
• Improved chemical stability
• Lower impurity formation
• Better dose recovery from the package
• Reduced microbial growth after opening
• Improved disintegration under pediatric-use conditions
• Reduced container adsorption or drug loss

A claim that merely recites conventional excipients at routine concentrations is vulnerable to obviousness challenges. A stronger estate would combine a narrow excipient range with a defined stability or sensory result.

What is the Orange Book status of prednisolone sodium phosphate?

Prednisolone sodium phosphate products are regulated as small-molecule drugs, not biologics. They may be approved through abbreviated new drug applications when the reference product and dosage form permit an ANDA pathway.

The FDA Orange Book identifies reference-listed drugs, approved abbreviated applications, therapeutic-equivalence evaluations, patents, and regulatory exclusivity where applicable.[5] For a current product-specific assessment, the relevant review must distinguish:

1. The active ingredient, prednisolone sodium phosphate.
2. The dosage form, such as oral solution or orally disintegrating tablet.
3. The strength.
4. The reference-listed drug.
5. Any listed patents.
6. Any remaining regulatory exclusivity.
7. The therapeutic-equivalence code.

The historical product landscape includes branded prednisolone sodium phosphate products such as Orapred and Orapred ODT, along with generic oral solutions and tablets. Core exclusivity associated with these older products has expired. Any current commercial barrier is more likely to arise from product-specific formulation patents, regulatory requirements, manufacturing capacity, or market economics than from active new-chemical-entity exclusivity.[1,5]

When does prednisolone sodium phosphate lose exclusivity?

Prednisolone sodium phosphate lost composition-of-matter exclusivity long ago. The active ingredient is not an emerging molecule with a pending five-year new chemical entity period. Current products generally compete in a mature generic market.

Potential historic or product-specific exclusivities include:

• Original NDA exclusivity
• Three-year exclusivity for a new clinical investigation supporting a modified product
• Pediatric exclusivity
• Orphan-drug exclusivity, if applicable to a qualifying indication
• Formulation or method-of-use patent rights

Those periods do not restore exclusivity to the active ingredient itself. The commercial question is whether a particular product has an unexpired patent or regulatory protection that restricts an ANDA or 505(b)(2) entrant.

For most development programs, the practical assumption should be that prednisolone sodium phosphate is open to generic competition, subject to confirmation of current Orange Book listings, label-specific patents, and any litigation involving the selected reference product.

What generic entry risks exist for prednisolone sodium phosphate?

Generic entry risk is high for conventional oral solutions and standard tablets because:

• The active ingredient is established.
• The products have straightforward routes of administration.
• The clinical use is well understood.
• Several generic manufacturers can potentially develop the product.
• Physicians and pharmacies are familiar with corticosteroid substitution.
• The product does not require a complex device or biologic manufacturing process.

Risk is lower for products with meaningful technical differentiation, including:

• A stable, preservative-free multidose system
• A proprietary oral syringe and bottle interface
• An ODT with superior moisture resistance
• A highly effective pediatric taste-masking platform
• A sterile ophthalmic formulation with reduced preservative exposure
• A product requiring specialized aseptic or low-bioburden processing

The strongest defense is usually not a broad patent on the drug. It is a combination of narrow formulation claims, trade secrets, regulatory know-how, qualified suppliers, and reliable commercial execution.

Are Paragraph IV challenges relevant to prednisolone sodium phosphate?

Paragraph IV certification is relevant when an ANDA applicant asserts that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed. A Paragraph IV notice can trigger patent litigation and a potential 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory conditions.[6]

For prednisolone sodium phosphate, Paragraph IV risk is most relevant to:

• Branded oral solutions with listed formulation patents
• ODT products with drug-delivery patents
• Ophthalmic products with formulation or container claims
• New 505(b)(2) products with listed patents
• Products using a proprietary dosing device

A generic sponsor should assess whether listed patents claim the active ingredient, dosage form, formulation, method of use, or packaging. A branded sponsor should avoid relying on weak excipient claims that cover routine combinations already present in the prior art.

What commercial opportunities exist for prednisolone sodium phosphate?

Pediatric oral liquids

Pediatric oral solution is the clearest opportunity because dose flexibility is clinically important and caregiver experience directly affects adherence. Commercial differentiation can focus on:

• Alcohol-free composition
• Sugar-free composition
• Lower-sorbitol or polyol-reduced formula
• Improved flavor persistence
• Ready-to-use product with no reconstitution
• Oral syringe calibrated for common pediatric doses
• Small-volume high-concentration presentation
• Tamper-evident, child-resistant packaging

A high-concentration product can reduce administration volume, but it increases the importance of taste masking and dosing-error controls. The concentration should be selected alongside the intended dosing device and common prescription instructions.

Preservative-free unit-dose products

Unit-dose oral liquids may appeal to hospitals, pediatric clinics, emergency departments, and patients with preservative concerns. The opportunity is strongest where contamination risk, portability, or institutional dispensing has economic value.

The tradeoff is higher packaging cost and reduced flexibility for patients requiring variable doses.

Orally disintegrating tablets

An ODT can compete on convenience, especially for patients who cannot swallow conventional tablets but do not need a liquid. Product development should focus on:

• Rapid disintegration
• Low friability
• Low moisture uptake
• Acceptable mouthfeel
• Dose uniformity
• Packaging that protects against humidity

ODTs may have stronger patent potential than a conventional oral solution, but the market is smaller and technical development is more demanding.

Ophthalmic formulations

Prednisolone sodium phosphate ophthalmic products can create opportunities in sterile manufacturing and preservative design. Commercial differentiation may include:

• Preservative-free single-dose containers
• Reduced ocular irritation
• Improved drop delivery
• Lower extractables and leachables
• Container designs that reduce tip contamination

Ophthalmic development has higher quality and manufacturing barriers than oral liquids because sterility, particulate control, container closure integrity, and ocular tolerability must be demonstrated.

Contract manufacturing and licensing

A company with a validated taste-masking platform, sterile ophthalmic capability, or pediatric packaging system can license technology to generic manufacturers. The most attractive licensing targets are manufacturers with:

• Existing corticosteroid distribution
• Pediatric or hospital sales channels
• ANDA development capacity
• Established bottle and syringe supply chains
• Geographic access to regulated markets

Licensing economics will depend on whether the technology creates a differentiated product or only reduces development cost. A formulation platform that applies to multiple corticosteroids has greater value than a single-product excipient combination.

How should an excipient development program be structured?

A practical development sequence is:

1. Screen pH, buffer, sweetener, flavor, preservative, and viscosity combinations.
2. Establish assay, related substances, pH, osmolality, viscosity, microbial limits, and preservative performance methods.
3. Run forced-degradation studies under acidic, basic, oxidative, thermal, and photolytic conditions.
4. Evaluate container compatibility, adsorption, extractables, and leachables.
5. Conduct pediatric-focused sensory testing.
6. Confirm dose delivery through the intended syringe and bottle system.
7. Perform accelerated and long-term stability studies under ICH conditions.[7]
8. Map the final composition against the FDA Inactive Ingredient Database and relevant pharmacopeial standards.[8]
9. Assess ANDA or 505(b)(2) pathway requirements.
10. File composition, process, packaging, and device patents before public disclosure.

The development team should avoid treating excipient selection as a late-stage optimization. Taste, pH, viscosity, preservative performance, and packaging interact. A formulation that passes chemical stability may fail on palatability or delivered-dose accuracy.

How does prednisolone sodium phosphate compare with other corticosteroids?

Product type	Relative formulation opportunity	Main commercial barrier
Prednisolone sodium phosphate oral solution	High for pediatric taste and dosing	Mature generic competition
Prednisolone acetate suspension	High technical complexity	Suspension uniformity and ocular performance
Dexamethasone oral solution	Moderate	Established generic supply
Methylprednisolone tablets	Lower for liquid-focused strategies	Strong tablet substitution
Budesonide oral suspension	Higher specialty value	More complex formulation and indication-specific competition

Prednisolone sodium phosphate has an advantage in aqueous solubility and pediatric dose flexibility. Its disadvantage is the lack of strong molecule-level exclusivity and the presence of established generic alternatives.

What manufacturing and intellectual-property barriers matter most?

The main manufacturing barriers are not synthesis of the active ingredient. They are:

• Reliable control of phosphate ester degradation
• Consistent pH adjustment
• Taste-masking reproducibility
• Microbial control in multidose liquids
• Low bioburden or aseptic processing for sterile products
• Moisture protection for ODTs
• Accurate dose delivery from the final package
• Supply continuity for specialized flavors, preservatives, and packaging components

Trade secrets may be more valuable than patents for flavor systems, mixing order, pH adjustment, deaeration, filtration, and filling parameters. A patent estate should protect the commercial formulation while confidential process controls protect manufacturing performance.

Key Takeaways

• Prednisolone sodium phosphate is a mature, generic corticosteroid with no meaningful composition-of-matter exclusivity.
• The strongest excipient opportunity is a pediatric oral solution optimized for taste, dose accuracy, and stability.
• Alcohol-free, sugar-free, preservative-minimized, and unit-dose products offer differentiated commercial positions.
• ODT and ophthalmic products offer greater technical and patent potential but require higher development investment.
• Formulation patents should tie excipient ranges to measurable stability, taste, delivery, or tolerability results.
• Paragraph IV risk depends on current Orange Book-listed patents for the selected reference product, not on the old active ingredient itself.
• The most durable competitive advantage is a combined package of formulation know-how, device integration, manufacturing controls, and targeted intellectual property.

FAQs

Can prednisolone sodium phosphate be formulated without preservatives?

Yes. A preservative-free product can use unit-dose packaging, aseptic processing, or a validated multidose contamination-control system. The commercial tradeoff is higher packaging and manufacturing cost.

Which excipient most improves prednisolone sodium phosphate taste?

No single excipient reliably solves the problem. Taste performance usually depends on the combined selection of sweetener, flavor, buffer, viscosity modifier, and drug concentration. Sensory testing is required to identify the best system.

Is prednisolone sodium phosphate suitable for a 505(b)(2) product?

Potentially. A 505(b)(2) strategy may be relevant for a new dosage form, delivery system, concentration, indication, preservative-free presentation, or other change that cannot rely entirely on an ANDA pathway. The regulatory strategy depends on the reference product and the extent of clinical or comparative data required.[9]

Does prednisolone sodium phosphate have biosimilar competition?

No. Prednisolone sodium phosphate is a small-molecule drug. Competition occurs through generic drug pathways, including ANDAs, rather than biosimilar applications under the Public Health Service Act.

What is the best commercial packaging for a pediatric product?

An amber or otherwise light-protective bottle paired with a calibrated oral syringe is a standard starting point. Unit-dose sachets or cups may support preservative-free positioning, while bottle-adapter systems can improve dose recovery and reduce caregiver errors.

References

1. U.S. Food and Drug Administration. (n.d.). Orapred ODT (prednisolone sodium phosphate) prescribing information. FDA Drugs@FDA.

2. U.S. Food and Drug Administration. (n.d.). Prednisolone sodium phosphate oral solution prescribing information. FDA labeling database.

3. DailyMed. (n.d.). Prednisolone sodium phosphate drug labels. National Library of Medicine.

4. United States Pharmacopeia. (2023). USP General Chapter <51>: Antimicrobial effectiveness testing. United States Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

6. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.

7. International Council for Harmonisation. (2003). ICH Q1A(R2): Stability testing of new drug substances and products.

8. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.

9. U.S. Food and Drug Administration. (2022). Applications covered by section 505(b)(2). FDA.